During double blind treatment : Cumulative occurrence of VTE assessed by ultrasound for all patients at 28±4 days after randomization (or earlier if symptomatic VTE) and/or V/Q lung scan for symptomatic patients ; Major hemorrhagic complications.
Occurrence of VTE between Day 1 and Day 90±10, Mortality at the end of Double-Blind Treatment, at 3 and 6 months
Minor plus major hemorrhagic complications during Double-Blind Treatment.
40 Years and older (Adult, Senior)
February 16, 2004
January 11, 2011
Sanofi-Aventis Bridgewater, New Jersey, United States
Sanofi-Aventis Buenos Aires, Argentina
Sanofi-Aventis North Ryde, Australia
(and 17 more...)
† Study has passed its completion date and status has not been verified in more than two years.